UNASSIGNED:非甾体类抗炎加剧的呼吸系统疾病(N-ERD)的特征是Samter三联征:慢性鼻窦炎伴鼻息肉,哮喘,和对NSAIDs的非过敏性超敏反应。其诊断基于完整的临床病史和阿司匹林(ASA)激发试验。医学治疗包括生物药物和ASA脱敏。
UNASSIGNED:本研究旨在评估N-ERD患者接受功能性内窥镜手术(FES)的临床反应,其次是ASA脱敏和维持治疗,这是在智利进行的第一项前瞻性队列研究。
UNASSIGNED:我们对12例接受FES治疗的N-ERD患者进行了1年的随访,脱敏,与ASA的维护。对于每个控件,药物评分,鼻窦症状学(SNOT-22),PEF(峰值呼气流量),鼻息肉病(Lildholdt评分),并记录不良反应的出现。在基线和12个月随访时进行鼻旁腔的计算机断层扫描(CT),以计算Lund-Mackay评分。
未经证实:患者在FES后出现SNOT-22减少,维持在12个月(p=0.002);表现出最大减轻的症状是感到尴尬和鼻塞。Lildholdt评分也显着降低(p=0.001);仅在三名患者中,鼻息肉复发,都很小。PEF显示出3.3%的轻微不显著的增加。总的来说,75%的患者有不良反应,最常见的是腹痛(66.7%),但在1年的随访中,12例患者均未需要停用阿司匹林治疗.Lund-Mackay评分显著降低6.6分(p<0.001)。
UNASSIGNED:ASA脱敏在减轻N-ERD患者的上呼吸道和下呼吸道症状方面是安全有效的,并且可以延迟鼻息肉的复发,尽管它不能免于不利影响,绝大多数是温和的。
UNASSIGNED: Nonsteroidal anti-inflammatory exacerbated respiratory disease (N-ERD) is characterized by the Samter triad: chronic rhinosinusitis with nasal polyps, asthma, and nonallergic hypersensitivity to NSAIDs. Its diagnosis is based on a complete clinical history and an aspirin (ASA) challenge test. Medical treatments include biological drugs and ASA desensitization.
UNASSIGNED: This study aims to evaluate the clinical response of patients with N-ERD undergoing functional endoscopic surgery (FES), followed by ASA desensitization and maintenance treatment, being the first prospective cohort study carried out in Chile.
UNASSIGNED: We conducted 1-year follow-up of 12 patients with N-ERD treated with FES, desensitization, and maintenance with ASA. For each control, the medication score, sinonasal symptomatology (SNOT-22), PEF (peak expiratory flow), nasal polyposis (Lildholdt score), and the appearance of adverse effects were recorded. Computed tomography (CT) of the paranasal cavities was performed at baseline and at the 12-month follow-up to calculate the Lund-Mackay score.
UNASSIGNED: Patients presented a reduction of SNOT-22 after the FES, which was maintained at 12 months (p = 0.002); the symptoms that showed the greatest reduction were feeling embarrassed and nasal obstruction. The Lildholdt score was also significantly reduced (p = 0.001); in only three patients, the nasal polyps recurred, and all were small. The PEF showed a slight nonsignificant increase of 3.3%. In total, 75% of patients had an adverse effect, the most frequent being abdominal pain (66.7%), but none of the 12 patients required discontinuation of aspirin treatment in 1-year follow-up. The Lund-Mackay score had a significant reduction of 6.6 points (p < 0.001).
UNASSIGNED: ASA desensitization is safe and effective in reducing upper and lower respiratory symptoms in patients with N-ERD and delays the reappearance of nasal polyps, although it is not exempt from adverse effects, with the vast majority being mild.